

CASE 4-30443B

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV19522752148

Express Mail Label Number

November 5, 2002

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1644

FARRIES ET AL.

APPLICATION NO: 09/875,519

FILED: JUNE 6, 2001

FOR: DOWN-REGULATED RESISTANT C3 CONVERTASE

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

This Information Disclosure Statement is being filed in accordance with 37 C.F.R. §1.97(c).
A letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/142,334 filed September 4, 1998, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).


Respectfully submitted,

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6940



Hesna J. Pfeiffer
Attorney for Applicants
Reg. No. 22,640

Date: 11/5/02



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV19522752148
Express Mail Label Number

November 5, 2002
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1644

FARRIES ET AL.

APPLICATION NO: 09/875,519

FILED: JUNE 6, 2001

FOR: DOWN-REGULATED RESISTANT C3 CONVERTASE

RECEIVED

NOV 08 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

FEE LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Please charge Deposit Account No. 19-0134 in the name of Novartis Corporation in the amount of \$180 for payment of the fee pursuant to 37 CFR §1.17(p) for the submission of an Information Disclosure Statement under 37 CFR §1.97(c).

An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis Corporation.

Respectfully submitted,

Hesna J. Pfeiffer
Attorney for Applicants
Reg. No. 22,640

Novartis Pharmaceuticals Corporation
Patent and Trademark Dept.
564 Morris Avenue
Summit, NJ 07901-1027
(908) 522-6940
Date: 11/5/02